PeptiMimesis

Illkirch-graffenstaden, France Founded: 2015 • Age: 11 yrs
Transmembrane therapeutic peptides are developed for oncology and immune diseases.

About PeptiMimesis

PeptiMimesis is a Healthcare company based in Illkirch-graffenstaden (France) founded in 2015. Transmembrane therapeutic peptides are developed for oncology and immune diseases. PeptiMimesis has raised $2.14 million across 2 funding rounds from investors including Capital Grand Est. PeptiMimesis offers products and services including Therapeutic Peptides. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.

Company details

PeptiMimesis was founded in 2015 and is based in Illkirch Graffenstaden, France. Focus is placed on developing transmembrane therapeutic peptides targeting oncology and immune diseases. Internal assets are advanced to key value inflection points prior to out-licensing to pharmaceutical partners. Partnerships are sought with pharma and biotech entities using the companys unique technology platform.

  • Headquarters Illkirch-graffenstaden, France
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website peptimimesis.com
Operational Areas
Key Metrics
  • Total Equity Funding
    $2.14M (USD)

    in 2 rounds

  • Latest Funding Round
    $740K (USD), Seed

    Mar 2017

  • Investors

Products & Services of PeptiMimesis

PeptiMimesis offers a comprehensive portfolio of products and services, including Therapeutic Peptides.

Therapeutic Peptides
Biotech Product

Peptides that interfere with receptor dimerization for oncology treatment

Funding Insights of PeptiMimesis

PeptiMimesis has successfully raised a total of $2.14M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $740 thousand completed in March 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $2.14M
  • Total Rounds 2
  • Last Round Seed β€” $740,000
  • First Round $1.4M

    (Apr 2016)

  • Investors Count 1

All 2 funding rounds of PeptiMimesis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2017$740,000Seed––
Apr 2016$1.4MSeed––
Valuation history

1 investors in total: 1 institutional.

Investors in PeptiMimesis

PeptiMimesis has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Capital Grand Est.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Investment support is provided to businesses in Grand Est region.
capitalgrandest.euSchiltigheim, France
Premium access

Investor details for PeptiMimesis

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of PeptiMimesis

1 people are tracked at PeptiMimesis (1 in leadership).

NameRoleGroup
Marjorie Sidhoum
Chief Executive OfficerLeadership
Premium access

Complete people profiles for PeptiMimesis

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of PeptiMimesis

3 dated milestones of PeptiMimesis across 2 years, from founding to its latest funding, stage changes and deals.

  1. Founded PeptiMimesis is founded.
  2. Funding First funding round of $1.4M.
  3. Funding Latest funding round, Seed, of $740K.
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about PeptiMimesis

PeptiMimesis was founded in 2015 and raised its 1st funding round 1 year after it was founded.

PeptiMimesis is headquartered in Illkirch-graffenstaden, France. It is registered at Illkirch-graffenstaden, Bas-rhin, France.

PeptiMimesis is a funded company, having raised a total of $2.14M across 2 funding rounds to date. The company's 1st funding round was a Seed of $1.4M, raised on Apr 2016.

PeptiMimesis was founded in 2015 and is based in Illkirch Graffenstaden, France. Focus is placed on developing transmembrane therapeutic peptides targeting oncology and immune diseases. Internal assets are advanced to key value inflection points prior to out-licensing to pharmaceutical partners. Partnerships are sought with pharma and biotech entities using the companys unique technology platform.

PeptiMimesis offers Therapeutic Peptides.

PeptiMimesis has 1 investor. Key investors include Capital Grand Est.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available